BioMed Research International / 2015 / Article / Tab 2

Review Article

In Vivo Anti-Candida Activity of Phenolic Extracts and Compounds: Future Perspectives Focusing on Effective Clinical Interventions

Table 2

Phenolic compounds with in vivo activity against Candida species.

CompoundClassOriginConditionCandida spp.PurposeAnimal modelExposureDosesReference

Curcuminoids: curcumin and piperine PolyphenolsCommercial standardsSystemic murine model of infectionC. albicansAntifungal potential and related modes of actionSwiss albino mice1st dose + 2nd dose after 6 h of the first, during 2 daysCurcumin alone: 100 mg/kg of body weight
Curcumin + Piperine: 100 and 20 mg/kg of body weight

Pterostilbene (PTE)Stilbene-derived PhytoalexinLaboratorial synthesisCentral venous catheter infectionC. albicansAntibiofilm potentialSprague-Dawley rats72 h of incubation500 µL liquid containing different concentrations of PTE (0, 16, 32, and 64 µg/mL)[86]

Riccardin D (RCD)Macrocyclic bisbibenzylChinese liverwort DumortierahirsuteIntravenous catheter infectionC. albicansAntibiofilm (prophylactic and therapeutic) potentialNew Zealand white rabbitsProphylactic: 8 h
Therapeutic: 8 h per day during consecutive 5 days
Prophylactic: Groups II, III, and IV, 300 µL of RCD solution (8, 16, and 64 µg/mL, resp.), Group VI, 300 µL of FLC (4 µg/mL) plus RCD solution (16 µg/mL)
Therapeutic: 300 µg (8, 16, and 64 µg/mL, resp.) was injected after 24 hours of infection